Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I'm still ...

United Kingdom, 15 th January 2025: Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as ...

The successful and safe delivery of therapeutics relies on understanding how easily drugs can pass through biological ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

but what we have done is engineered it specifically for use in vivo,” Phil Johnson, CEO of Interius BioTherapeutics, said. “That took us a while. That was a couple of years’ long process to ...

The global 3D cell culture market is poised for exceptional expansion, with industry experts forecasting a substantial growth from USD 1.26 billion in 2023 to an estimated USD 3 billion by 2033. This ...

Tissue engineering utilizes 3D printing and bioink to grow human cells on scaffolds, creating replacements for damaged ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...